These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 1726963)
1. Importance of conformation on the neutralizing antibody response to HIV-1 gp120. Steimer KS; Haigwood NL Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963 [TBL] [Abstract][Full Text] [Related]
2. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides. Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949 [TBL] [Abstract][Full Text] [Related]
3. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies]. Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660 [TBL] [Abstract][Full Text] [Related]
4. Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons. Haigwood NL; Nara PL; Brooks E; Van Nest GA; Ott G; Higgins KW; Dunlop N; Scandella CJ; Eichberg JW; Steimer KS J Virol; 1992 Jan; 66(1):172-82. PubMed ID: 1727480 [TBL] [Abstract][Full Text] [Related]
5. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
6. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice. Boudet F; Theze J; Zouali M Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435 [TBL] [Abstract][Full Text] [Related]
7. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Doe B; Steimer KS; Walker CM Eur J Immunol; 1994 Oct; 24(10):2369-76. PubMed ID: 7523139 [TBL] [Abstract][Full Text] [Related]
8. Identification of a new neutralizing epitope conformationally affected by the attachment of CD4 to gp120. Kang CY; Hariharan K; Posner MR; Nara P J Immunol; 1993 Jul; 151(1):449-57. PubMed ID: 7686944 [TBL] [Abstract][Full Text] [Related]
9. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines. VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123 [TBL] [Abstract][Full Text] [Related]
10. Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies. Haigwood NL; Shuster JR; Moore GK; Lee H; Skiles PV; Higgins KW; Barr PJ; George-Nascimento C; Steimer KS AIDS Res Hum Retroviruses; 1990 Jul; 6(7):855-69. PubMed ID: 2390335 [TBL] [Abstract][Full Text] [Related]
11. Two new human monoclonal antibodies against HIV type 1 glycoprotein 120: characterization and neutralizing activities against HIV type 1 strains. Février M; Boudet F; Deslandres A; Theze J AIDS Res Hum Retroviruses; 1995 Apr; 11(4):491-500. PubMed ID: 7543271 [TBL] [Abstract][Full Text] [Related]
12. Structural and immunological reactivity of the principal neutralizing determinant V3 of glycoprotein gp120 of HIV-1. Borbe HC; Stuber G; Wagner R; Wolf H; Modrow S J Pept Sci; 1995; 1(2):109-23. PubMed ID: 9222988 [TBL] [Abstract][Full Text] [Related]
13. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203 [TBL] [Abstract][Full Text] [Related]
14. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645 [TBL] [Abstract][Full Text] [Related]
15. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Pantophlet R; Wilson IA; Burton DR Protein Eng Des Sel; 2004 Oct; 17(10):749-58. PubMed ID: 15542540 [TBL] [Abstract][Full Text] [Related]
16. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Bower JF; Li Y; Wyatt R; Ross TM Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193 [TBL] [Abstract][Full Text] [Related]
17. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles. Kang CY; Luo L; Wainberg MA; Li Y Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338 [TBL] [Abstract][Full Text] [Related]
18. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies. Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034 [TBL] [Abstract][Full Text] [Related]
19. GP120: target for neutralizing HIV-1 antibodies. Pantophlet R; Burton DR Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]